Fig. 2
Overall and disease-free survival analysis of 204 patients diagnosed with middle risk: disease-free survival of patients with different sites in the whole group of patients (A); disease-free survival of different Ki-67 indices (B); disease-free survival of 140 patients with tumors located in the stomach with different Ki-67 indices (C); the overall survival of the whole group of patients with different TKI treatment methods (D); the overall survival of 140 patients with tumors located in the stomach with different Ki-67 indices (E) the overall survival of 140 patients with tumors located in the stomach with different TKI treatment methods (F); the overall survival of 64 patients with different Ki-67 indices in non-stomach tumors (G); the overall survival of 64 patients with tumors located in non-stomach with different IM treatment methods (H)